Literature DB >> 24740042

Hepatitis C drugs not reaching poor.

Ewen Callaway.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24740042     DOI： 10.1038/508295a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  14 in total

1.  Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle.

Authors:  Shanshan He; Kelin Li; Billy Lin; Zongyi Hu; Jingbo Xiao; Xin Hu; Amy Q Wang; Xin Xu; Marc Ferrer; Noel Southall; Wei Zheng; Jeffrey Aubé; Frank J Schoenen; Juan J Marugan; T Jake Liang; Kevin J Frankowski
Journal:  J Med Chem       Date:  2017-07-13       Impact factor: 7.446

2.  Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability?

Authors:  Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-06

3.  A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C.

Authors:  Christopher Koh; Preeti Dubey; Ma Ai Thanda Han; Peter J Walter; H Martin Garraffo; Pallavi Surana; Noel T Southall; Nathaniel Borochov; Susan L Uprichard; Scott J Cotler; Ohad Etzion; Theo Heller; Harel Dahari; T Jake Liang
Journal:  Antiviral Res       Date:  2019-01-31       Impact factor: 5.970

4.  Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.

Authors:  Michael Logan; John Law; Jason Alexander Ji-Xhin Wong; Darren Hockman; Amir Landi; Chao Chen; Kevin Crawford; Juthika Kundu; Lesley Baldwin; Janelle Johnson; Anita Dahiya; Gerald LaChance; Joseph Marcotrigiano; Mansun Law; Steven Foung; Lorne Tyrrell; Michael Houghton
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

5.  Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells.

Authors:  Susanne Ziegler; Kathrin Skibbe; Andreas Walker; Xiaoyu Ke; Falko M Heinemann; Andreas Heinold; Juk Yee Mok; Wim J E van Esch; Dongliang Yang; Matthias Wölfl; Jörg Timm
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

Review 6.  Animal Models of Hepatitis C Virus Infection.

Authors:  Alexander Ploss; Amit Kapoor
Journal:  Cold Spring Harb Perspect Med       Date:  2020-05-01       Impact factor: 6.915

Review 7.  Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.

Authors:  Catherine Fauvelle; Che C Colpitts; Zhen-Yong Keck; Brian G Pierce; Steven K H Foung; Thomas F Baumert
Journal:  Expert Rev Vaccines       Date:  2016-06-13       Impact factor: 5.683

8.  Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus.

Authors:  Nikolien van de Ven; Joe Fortunak; Bryony Simmons; Nathan Ford; Graham S Cooke; Saye Khoo; Andrew Hill
Journal:  Hepatology       Date:  2015-02-09       Impact factor: 17.425

9.  Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.

Authors:  Shanshan He; Jingbo Xiao; Andrés E Dulcey; Billy Lin; Adam Rolt; Zongyi Hu; Xin Hu; Amy Q Wang; Xin Xu; Noel Southall; Marc Ferrer; Wei Zheng; T Jake Liang; Juan J Marugan
Journal:  J Med Chem       Date:  2016-02-01       Impact factor: 7.446

Review 10.  Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus.

Authors:  Thomas R Fuerst; Brian G Pierce; Zhen-Yong Keck; Steven K H Foung
Journal:  Front Microbiol       Date:  2018-01-15       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.